What if Kalydeco was dosed together with VX-809 from the beginning
At one point during the recent webcast by Vertex, Jeff Leiden said the company was "all in" when referring to their CF franchise commitment. They must be confident about the success of their CF drugs to make this comment. My opinion is that their market cap should be much higher based on Vertex progress in cystic fibrosis alone. Everything else from their hepatitis C drugs to their extensive pipeline of drugs for other diseases is a bonus.